Oh well thats how it goes for Biotech
Sell now and lose your opportunity. There are enough stories to validate this company's business.
Before ibrutinib gets any sales, it must get regulatory approval, which isn't seen until 2015 because the company has to complete a late-stage trial, analysts say. In a larger trial, the potential exists for unforeseen complications or weaker efficacy readings,
Other companies are pursuing drugs that target the same enzyme, including developmental CLL drugs at Celgene Corp. (CELG), and Gilead Sciences Inc. (GILD), which seems to be moving faster with the studies of its GS-1101, CAL 101 and other, The market may not be big enough, soon enough, to support the revenue implied by the PCYC stock's recent valuation. This is exciting though so stay tuned. GA101, TRU016, CAL101, University of Pennsylvania research, John Kanzius Foundation. Also watch further development with the Nanobody King... ABLYNX in Netherlands ABLX.BR ...... US ADR is ABLYF, and XMAB from Xencor in California. It has several serious partnerships to beat PCYC to the finish line. GLTA
His analysis is clear, succinct and very real. This is one position one should hold through 2013. It will be very exciting and could move to $5.00 when institutions climb aboard.
Seems Genentech sees the opportunity we all see. There is some potential for speculation here. GLTA
"michigan has huge hopes for tiny stem cells michigan news
Good article to boot. Suggest those spec investors take a look at it.
Not a sucker at this level with so much promise. Screw the naysayers there is potential here. they are 90% done with all the prerequisites. A little safety issue will be resolved. PERIOD.
Breakeven point will be even lower. Thank you to all who sold.
For such a great price and with a panel of clowns that made such a looney safety issue decision i put my money on DVAX. Big pharma may also look at this position as an great opportunity to come to the rescue. Stay tuned. There will be lotsa volatility today when clowns sell and market players buy.
this is way overdone in comparison to IDIX or BMY. DVAX actually has the better drug. The chances of FDA and European approval are far better than 50% so i am holding on thru this bumpy irrational selling time. GLTA this goes with investing in Biotech.
the markets will squeeze and tighten as the drop dead date nears for the fiscal cliff. Lotsa other distractions to make watching the evening news more dicey. UVXY is a good hedge.
sit tight after the hoopla is said and done those with gain will lock in before the fiscal cliff. I would prefer to sit on the sidelines.
Looks like the cliff is a coming. He continues to want to mess with divididend, capital gains, and rate increases on the wealthy. Class warfare tactic 101 again for the next 4 years.